Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage biopharmaceutical company developing the bifunctional antibody ficerafusp alfa for solid tumors. As a public issuer, Bicara submits periodic and current reports that provide detail on its financial position, research and development spending, and key clinical and corporate events.
Among the filings available for review are Form 10-K annual reports and Form 10-Q quarterly reports, which describe operating expenses, including research and development and general and administrative costs, as well as cash, cash equivalents, and investments. These documents give insight into how Bicara funds the pivotal FORTIFI-HN01 trial in recurrent/metastatic head and neck squamous cell carcinoma and its Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer.
Form 8-K current reports, such as those referenced in the provided data, furnish press releases on quarterly financial results and business updates. These filings often summarize recent clinical milestones for ficerafusp alfa, including dose-optimization progress, expansion cohort data, and regulatory developments like Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Investors can also use this page to access exhibits attached to Bicara’s SEC filings, which may include detailed financial statements, risk factor discussions, and other disclosures relevant to evaluating a clinical-stage biotechnology company. Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly identify information on operating expenses, cash runway, clinical trial status, and other factors that influence the outlook for BCAX.
Bicara Therapeutics, Inc. (BCAX) has filed a registration statement on Form S-3 establishing a shelf for securities and incorporates by reference prior SEC filings including its Form 10-K and amendments. The prospectus discloses clinical data for an HPV-negative HNSCC population with a PD-L1 combined positive score ≥1 and reports a 2-year overall survival rate of 46%. The document describes tax and withholding rules for non-U.S. holders, including a 30% default U.S. withholding rate and treaty-reduced rates where applicable. The filing lists underwriting and sales agreements, corporate charters and bylaws, opinions from Goodwin Procter LLP, consent from KPMG LLP, and trustee eligibility statements. Multiple exhibits and effective dates, including signatures dated October 3, 2025, are included.
Lara Meisner, Chief Legal Officer of Bicara Therapeutics (BCAX), reported option exercise and an immediate sale on 09/29/2025 under a pre-established plan. The reporting person exercised a stock option with a $9.2435 exercise price to acquire 33,807 shares and concurrently sold 33,807 shares at $14.75 per share, leaving 0 shares of common stock held directly after the sale. The option granting those shares vests on a schedule that began with a 25% vesting on 08/13/2025 and continues in twelve equal quarterly installments; the option expires 08/13/2034. The filing notes the transactions were executed pursuant to a Rule 10b5-1 trading plan adopted November 13, 2024.
Bicara Therapeutics (BCAX) Form 144 reports a proposed sale of 33,807 common shares through Morgan Stanley Smith Barney LLC, with an aggregate market value of $395,879.97, representing part of the issuer's outstanding 54,562,841 shares. The shares were acquired and will be sold on 09/29/2025 upon exercise of stock options, with payment in cash. The filing also discloses 10b5-1 plan sales by Lara Meisner of 15,829 shares on 09/15/2025 for gross proceeds of $181,893.96. The filer attests there is no undisclosed material adverse information and includes standard Rule 144 and 10b5-1 representations.
Lara Meisner, Chief Legal Officer and director of Bicara Therapeutics (BCAX), reported insider transactions on 09/15/2025 executed under a Rule 10b5-1 trading plan adopted on 11/13/2024. She acquired 15,829 shares of Common Stock at an exercise price of $5.45 and simultaneously sold 15,829 shares at a weighted-average price of $11.49, with sale prices ranging from $11.34 to $11.73.
The filing also discloses two stock option grants exercisable at $5.45 that were affected by the transactions: one covering 6,085 underlying shares and another covering 9,744 underlying shares, each with vesting schedules described in the filing and expiration dates of 12/14/2033.
Vestal Point Capital, LP and Ryan Wilder report ownership of 5,000,000 shares of Bicara Therapeutics Inc. common stock, representing 9.2% of the outstanding shares based on 54,536,218 shares outstanding as of May 8, 2025. The reported interest is held by the Vestal Point fund and a managed account and is shown as shared voting and dispositive power (no sole voting or dispositive power).
The filing identifies Vestal Point as an investment manager and Mr. Wilder as its Chief Investment Officer and managing member. The Reporting Persons state the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
Bicara Therapeutics is a clinical-stage biopharmaceutical company advancing its lead bifunctional antibody, ficerafusp alfa, into late-stage testing. The company reported $436.6 million in cash and cash equivalents as of June 30, 2025 and an accumulated deficit of $285.3 million. Net losses were $27.4 million for the quarter and $64.2 million for the six months ended June 30, 2025, driven by higher research and development and general and administrative spending as Bicara scales clinical operations and manufacturing.
Bicara initiated the pivotal FORTIFI-HN01 Phase 2/3 program (combination with pembrolizumab) and maintains a collaboration with MSD to supply pembrolizumab for combination cohorts. R&D spending increased materially to support clinical and manufacturing activity, and management expects existing cash to fund operations into the first half of 2029. The company disclosed pending litigation alleging inventorship of patents and reiterated that it will require additional funding over time to advance development and commercialization.
Bicara Therapeutics Inc. filed a current report to note that it has released its financial results and business highlights for the quarter ended June 30, 2025. On August 12, 2025, the company issued a press release describing its quarterly performance and key developments.
The press release is attached as Exhibit 99.1 and is incorporated by reference for informational purposes, but is designated as furnished rather than filed under the Exchange Act. The filing also includes an Inline XBRL cover page data file as Exhibit 104.
Schedule 13G/A (Am. No. 1) filed for Bicara Therapeutics Inc. (BCAX) shows that investment entities affiliated with Invus have built a passive 9.6 % stake in the company’s common stock as of 30 Jun 2025.
- Invus Public Equities, L.P. directly owns 4,861,944 shares (8.9 %).
- Avicenna Life Sci Master Fund LP holds 355,025 shares (0.7 %).
- Through control of multiple GP/LLC vehicles, Raymond Debbane is deemed to beneficially own a combined 5,216,969 shares, representing the full 9.6 %.
Percentages are based on 54,536,218 shares outstanding reported in the issuer’s 13 May 2025 10-Q. The filing is made under Rule 13d-1(c) and includes the standard certification that the securities were not acquired to change or influence control, indicating a passive investment approach.
The appearance of a sophisticated life-sciences investor just below the 10 % threshold may improve market confidence and liquidity but does not signal activist intent at this stage.
Bicara Therapeutics Inc. (BCAX) – Form 4 insider filing dated 18 Jun 2025 reports transactions by Chief Legal Officer Lara Meisner.
Non-derivative activity: On 16 Jun 2025 Meisner exercised 15,829 options for common stock at an exercise price of $5.45 per share and immediately sold the same 15,829 shares at a weighted-average price of $10.43 (individual sales executed between $10.03-$10.84). As a result, her direct common-stock ownership fell to 0 shares.
Derivative holdings: Two option grants were partially exercised. After the transactions Meisner still directly holds 60,854 options with a $5.45 strike expiring 10 Dec 2033 and 97,443 options with the same strike and expiry, for a total of 158,297 remaining options.
- Grant #1 vests in 16 equal quarterly installments from 14 Dec 2023.
- Grant #2 vested 25 % on 27 Nov 2024; the balance vests in 12 equal quarterly installments thereafter.
Rule 10b5-1 plan: All trades were executed under a pre-arranged Rule 10b5-1 trading plan adopted on 13 Nov 2024, as disclosed in the Explanation of Responses.
The filing reflects routine option exercise and monetisation by an executive officer, with no change to derivative exposure but the elimination of directly held common shares.